Sepiapterin reductase inhibition selectively reduces inflammatory joint pain and increases urinary sepiapterin in the late phase.

Objective— To evaluate the anti-inflammatory and analgesic effect of sepiapterin reductase (SPR) inhibition in a mouse model of inflammatory joint disease and to evaluate sepiapterin as a non-invasive, translational biomarker of SPR inhibition/target engagement in mice and healthy human volunteers. Methods— The collagen antibody-induced arthritis (CAIA) mouse model was used to induce joint inflammation. The effect of pharmacological inhibition of SPR on heat, cold and mechanical threshold sensitivity and signs of inflammation was tested in mice. Urine from mice and healthy volunteers treated with SPR inhibitors were analyzed by HPLC for changes in sepiapterin levels. Results— CAIA presented joint inflammation with heat, mechanical and cold pain hypersensitivity (inflammatory acute phase), and heat, mechanical but not cold hypersensitivity without joint inflammation (post-inflammation; late phase). of inflammation were unaffected by SPR inhibition. Urinary BH4 levels were increased (100%; p<0.05) during inflammation and reduced (p<0.05) by SPR inhibition. Increased urinary sepiapterin levels in the presence of SPR inhibition were associated with high sensitivity (70– 85%) and specificity (82–88%) in both mice and healthy volunteers. Conclusion— SPR inhibition reduces pain associated with joint inflammation, showing potential utility as an analgesic strategy for inflammatory joint pain. SPR inhibition also increases urinary sepiapterin, indicating the potential of this measurement as a non-invasive biomarker of target engagement of SPR inhibitors, such as sulfasalazine (SSZ), a disease-modifying anti-rheumatic drug used as a first line treatment for rheumatoid arthritis (RA).

[1]  E. McNeill,et al.  The metabolite BH4 controls T cell proliferation in autoimmunity and cancer , 2018, Nature.

[2]  D. Hafler,et al.  Regulatory T cells in autoimmune disease , 2018, Nature Immunology.

[3]  M. Persson,et al.  Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials , 2018, Rheumatology.

[4]  D. Geschwind,et al.  Mechanistic Differences in Neuropathic Pain Modalities Revealed by Correlating Behavior with Global Expression Profiling , 2018, Cell reports.

[5]  L. Barbeito,et al.  Neopterin as a potential cytoprotective brain molecule. , 2015, Journal of psychiatric research.

[6]  J. Friedman,et al.  Urine sepiapterin excretion as a new diagnostic marker for sepiapterin reductase deficiency. , 2015, Molecular genetics and metabolism.

[7]  K. Channon,et al.  Reduction of Neuropathic and Inflammatory Pain through Inhibition of the Tetrahydrobiopterin Pathway , 2015, Neuron.

[8]  S. Hwang,et al.  Bacteria activate sensory neurons that modulate pain and inflammation , 2013, Nature.

[9]  K. Johnsson,et al.  Tetrahydrobiopterin Biosynthesis as an Off-Target of Sulfa Drugs , 2013, Science.

[10]  Kutty Selva Nandakumar,et al.  Collagen antibody-induced arthritis evokes persistent pain with spinal glial involvement and transient prostaglandin dependency. , 2012, Arthritis and rheumatism.

[11]  C. Woolf,et al.  Analgesia by inhibiting tetrahydrobiopterin synthesis. , 2012, Current opinion in pharmacology.

[12]  E. Werner,et al.  Tetrahydrobiopterin: biochemistry and pathophysiology. , 2011, The Biochemical journal.

[13]  K. Johnsson,et al.  A yeast-based screen reveals that sulfasalazine inhibits tetrahydrobiopterin biosynthesis. , 2011, Nature chemical biology.

[14]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update , 2010, Annals of the rheumatic diseases.

[15]  H. Sawada,et al.  Expression analysis of the aldo-keto reductases involved in the novel biosynthetic pathway of tetrahydrobiopterin in human and mouse tissues. , 2009, Journal of biochemistry.

[16]  Kutty Selva Nandakumar,et al.  Efficient promotion of collagen antibody induced arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis. , 2005, Journal of immunological methods.

[17]  H. Ishida,et al.  N-Acetyltransferase 2 Genotype-Related Efficacy of Sulfasalazine in Patients with Rheumatoid Arthritis , 2004, Pharmaceutical Research.

[18]  Kutty Selva Nandakumar,et al.  Collagen antibody induced arthritis. , 2007, Methods in molecular medicine.